Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

r at 5:45 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

The following posters will be presented by the investigators from The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital:

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild Type c-KIT And Potential Impact On Normal Hematopoiesis.  Session Name: Molecular Pharmacology, Drug Resistance: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Antileukemic Effects On FLT3-ITD Positive AML Cell Lines And Primary Cells: Session Name: Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The abstracts and posters can be accessed on the ASH website at http://hematology.org.

Third Quarter Results
Revenues were $7.7 million and $4.3 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $3.4 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $4.5 million and $8.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The decrease of $3.7 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, in which enrollment was completed in late 2011. 

General and administrative expenses were
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology ... today announced that Linda Powers , NW Bio CEO, will ... platform for solid tumor cancers and the Company,s multiple clinical ... , , , DATE: , , , Thursday, ... , , 12:15 PM EDT , , , , ...
(Date:5/6/2015)... SHANGHAI , May 6, 2015 Dr ... institute of Massey University, will deliver a speech at the ... 24-25 at the Shanghai New Expo Center.  ... he will introduce to attendees the topic: ,Potato Starch: ... Bulk-ingredients and Smart Foods., Co-editor of a ...
(Date:5/5/2015)... 5, 2015 Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens,  today announced that ... of America Merrill Lynch 2015 Health Care Conference on May ... Encore at the Wynn, Las Vegas NV. ... will be available through the investor relations section of Roka ...
(Date:5/5/2015)... Mass. , May 5, 2015 Psyche ... strategic alliance which offers a first-of-its-kind platform that helps ... access to lab results, transforms the way patients engage ... Luminate Health provides a HIPAA-compliant digital ... to access, manage, and understand their lab results, and ...
Breaking Biology Technology:NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3
... BOSTON, Jan. 4 PAREXEL International,Corporation (Nasdaq: PRXL ... on Wednesday, January 23, 2008 after the close of ... website at, http://www.parexel.com and on the PR Newswire ... conference call and live webcast at 10:00 a.m. ET,on ...
... SOUTH SAN FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, ... been named,General Counsel, a newly established position, and ... is a global life sciences,executive and corporate attorney ... early-stage companies in the US and,Europe. In the ...
... If Approved for Marketing in the United States, Trade Name Will be ... ... Daiichi Sankyo,Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: ... a New Drug,Application (NDA) for prasugrel to the U.S. Food and Drug ...
Cached Biology Technology:PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call 2Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 3Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 4
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... in the environmentand in environmental science laboratories. Because they ... and antifungal agents, silver nanoparticles increasingly are being used ... This, in turn, has raised concerns about what happens ... new research paper* adds an additional wrinkle: Nature may ...
... have almost lifted the curtain on the long-awaited era of the ... up a person can be deciphered for about that amount ... article in the current edition of Chemical & Engineering News (C&EN), ... of $100,000, by one conservative estimate, is necessary to analyze that ...
... expensive cancer drugs, dubbed "smart drugs" for their ability to ... are not effective in some patients. In two related studies, ... EGF receptor (EGFR), and found that a decoy receptor might ... intended target. "We know that smart drugs like ...
Cached Biology News:Silver cycle: New evidence for natural synthesis of silver nanoparticles 2Yale researchers explain why cancer 'smart drugs' may not be so smart 2
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: